Bristol-Myers Squibb Company (ETR:BRM)
Germany
· Delayed Price · Currency is EUR | Market Cap | 108.40B |
| Revenue (ttm) | 46.65B |
| Net Income (ttm) | -8.64B |
| Shares Out | n/a |
| EPS (ttm) | -4.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 2.26 (4.27%) |
| Ex-Dividend Date | Jan 3, 2025 |
| Volume | 613 |
| Average Volume | 1,527 |
| Open | 53.27 |
| Previous Close | 53.04 |
| Day's Range | 52.58 - 53.27 |
| 52-Week Range | 36.42 - 58.79 |
| Beta | 0.45 |
| RSI | 42.97 |
| Earnings Date | Feb 6, 2025 |
About ETR:BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
News
Insider trades: JPMorgan, Bristol-Myers Squibb among notable names this week
Discover notable insider trading updates from February 18-21, 2025. Key buys and sells across JPM, KMI, CVS, and more.
Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success
On February 6, Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to 'Strong Buy'.
Bristol-Myers Squibb (BMY) Announces Executive Vice President's Retirement
Bristol-Myers Squibb (BMY) Announces Executive Vice President's Retirement
Lightning Round: Own Arm Holdings for the long-term, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: Deere, Arm Holdings, Vital Farms, and Bristol-Myers Squibb.
Bristol Myers Squibb Announces Opdivo Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer
Bristol Myers Squibb (NYSE: BMY) today announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which evaluated Opdivo (nivolumab) in combination with platinum-doub...
Bristol-Myers Squibb Co (BMY) Announces Positive Five-Year Results for Sotyktu in Psoriasis ...
Bristol-Myers Squibb Co (BMY) Announces Positive Five-Year Results for Sotyktu in Psoriasis Treatment
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile Following five years of continuous Sotyktu treatment, clini...
Bristol-Myers Squibb Co (BMY) Announces Phase 3 Trial Results for Opdualagâ¢
Bristol-Myers Squibb Co (BMY) Announces Phase 3 Trial Results for Opdualagâ¢
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients with completely resected st...
Decoding Bristol-Myers Squibb Co (BMY): A Strategic SWOT Insight
Decoding Bristol-Myers Squibb Co (BMY): A Strategic SWOT Insight
Bristol-Myers Squibb Unusual Options Activity
Whales with a lot of money to spend have taken a noticeably bullish stance on Bristol-Myers Squibb . Looking at options history for Bristol-Myers Squibb (NYSE: BMY) we detected 10 trades. If we consi...
What's Going On With Bristol Myers Squibb Stock On Monday?
Bristol Myers Squibb & Co (NYSE: BMY) released topline data Monday from its Phase 2 TRANSCEND FL trial of Breyanzi (lisocabtagene maraleucel) for relapsed or refractory indolent B-cell non-Hodgkin ly...
Bristol-Myers Squibb: Cobenfy's Strong Launch And 2025 Growth Outlook
Bristol Myers Squibb Announces Positive Topline Results for Breyanzi (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi (lisocabtagene maraleucel) in adult patients with relapsed or refractory indolent B-cell non-Hodgkin...
Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
Trial met primary endpoint of overall response rate and key secondary endpoint of complete response rate With these data, Breyanzi demonstrates efficacy and manageable safety in a fifth cancer type, t...
Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down
Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent concerns. See why I rate BMY as a Hold.
US Stocks Likely To Open On A Mixed Note: Amazon, Pinterest, Take-Two Among Stocks To Watch
U.S. stocks could open on a mixed note on Friday after the averages closed at a record high on Thursday. Futures of major indices were down, while the Dow was marginally higher. Newell Brands Inc. (NA...
S&P 500 Gains For 3rd Session: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone
The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the “Fear” zone on Thursday. U.S. stocks settled mixed on Thursday, with the S&P...
Bristol-Myers Squibb targets $45.5B revenue for 2025 with cost savings and pipeline expansion
Bristol-Myers Squibb Company (BMY) Q4 2024 Earnings Conference Call Transcript
Bristol Myers Squibb (BMY) Q4 2024 Earnings Call Transcript
BMY earnings call for the period ending December 31, 2024.
Trade Tracker: Josh Brown sells Bristol Myers after buying it on Monday
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's selling Bristol Myers so quickly.
Highlights of Bristol-Myers Squibb’s Q4 2024 earnings report
Biotechnology company Bristol Myers Squibb (NYSE: BMY) reported lower profit for the fourth quarter of 2024, despite an increase in revenue. Net income attributable to shareholders was $72 million or ...
Dow Dips 150 Points; Bristol Myers Squibb Issues Weak Outlook
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 150 points on Thursday. The Dow traded down 0.35% to 44,715.15 while the NASDAQ rose 0.08% to 19,708.01. The S&...
Bristol Myers' stock decline in response to weak guidance is a gift to investors
The heart of our investment thesis in the drugmaker remains intact.